Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Ist Teil von
Clinical cancer research, 2009-05, Vol.15 (9), p.3094-3102
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2009
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
Purpose: Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers. To
identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.
Experimental Design: The first compound in this series, suitable for i.v. administration, has entered clinical development. To fully explore the
potential of Polo-like kinase 1 inhibition in oncology, we have profiled additional compounds and now describe a novel clinical
candidate.
Results: BI 6727 is a highly potent (enzyme IC 50 = 0.87 nmol/L, EC 50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties. First, BI 6727
has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high volume of distribution and a long terminal
half-life in mice ( V ss = 7.6 L/kg, t 1/2 = 46 h) and rats ( V ss = 22 L/kg, t 1/2 = 54 h). Second, BI 6727 has physicochemical and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules. Finally, BI 6727 shows marked antitumor
activity in multiple cancer models, including a model of taxane-resistant colorectal cancer. With oral and i.v. routes of
administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated
dosing schedules.
Conclusion: These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clinical studies have been initiated.